3 published articles
Selank has a notably clean interaction profile — no documented pharmacokinetic conflicts with commonly co-administered peptides. The interaction cautions that do exist relate to pharmacodynamic overlap: stacking Selank with other anxiolytic compounds risks additive CNS depression, and combining with stimulating peptides like Semax requires careful dose management.
A 12-week recovery cycle typically structures weeks 1–6 as a loading phase with higher-frequency administration, weeks 7–10 as a consolidation phase at reduced frequency, and weeks 11–12 as a taper. The specific peptide determines whether loading makes pharmacological sense — not all peptides have a loading rationale.
BPC-157 and TB-500 are the most commonly co-administered peptides in recovery protocols and no adverse interactions have been reported in either animal studies or user reports. Their mechanisms are complementary — BPC-157 addresses inflammatory signalling, TB-500 promotes cell migration — but no co-administration RCT exists.